How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,369 results for

Potassium Replacement

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Spot urine samples compared with 24-h urine samples for estimating changes in urinary sodium and potassium excretion in the China Salt Substitute and Stroke Study. Full Text available with Trip Pro

Spot urine samples compared with 24-h urine samples for estimating changes in urinary sodium and potassium excretion in the China Salt Substitute and Stroke Study. The capacity of spot urine samples for detecting changes in population sodium and potassium excretion is unclear.Changes in urinary sodium and potassium excretion, over a 6-month to 2-year interval, were measured from 24-h urine samples and estimated from spot urine samples using several published methods in 3270 Chinese. Additional (...) estimates were made by multiplying individual spot sodium and potassium concentrations by a single estimated 24-h urine volume derived from external data.The measured difference in 24-h urinary excretion between intervention and control groups was -0.35 g (95% CI: -0.68 to -0.02; P = 0.039) for sodium and 0.66 g (95% CI: 0.52 to 0.80; P < 0.001) for potassium, based upon 24-h urine samples. The corresponding estimates of sodium differences for the Tanaka (-0.06 g), Kawasaki (-0.09 g), Intersalt without

2019 International journal of epidemiology Controlled trial quality: uncertain

2. Glucose-insulin-potassium improves left ventricular performances after aortic valve replacement: a secondary analysis of a randomized controlled trial. Full Text available with Trip Pro

Glucose-insulin-potassium improves left ventricular performances after aortic valve replacement: a secondary analysis of a randomized controlled trial. Patients with left ventricular (LV) hypertrophy may suffer ischemia-reperfusion injuries at the time of cardiac surgery with impairment in left ventricular function. Using transesophageal echocardiography (TEE), we evaluated the impact of glucose-insulin potassium (GIK) on LV performances in patients undergoing valve replacement for aortic

2019 BMC Anesthesiology

3. Effectiveness and Safety of Potassium Replacement in Critically Ill Patients: A Retrospective Cohort Study. Full Text available with Trip Pro

Effectiveness and Safety of Potassium Replacement in Critically Ill Patients: A Retrospective Cohort Study. Rules of thumb for potassium replacement are used in intensive care units despite minimal empirical validation.To evaluate the effectiveness and safety of rule-of-thumb potassium replacement in critically ill patients with mild and moderate hypokalemia.A retrospective, observational study was done of patients with mild (potassium, 3-3.9 mEq/L) and moderate (potassium, 2-2.9 mEq/L (...) ) hypokalemia admitted to a medical intensive care unit who received potassium replacement. Expected and actual frequencies of replacement that achieved target potassium concentrations (≥ 4 mEq/L) were compared by using a χ2 test. Logistic regression analysis was used to assess whether rule-of-thumb administration affected the probability of target attainment within 24 hours of replacement.Serum potassium concentrations were checked within 24 hours after potassium replacement on 354 of 577 days (61.4%) when

2019 Critical care nurse

4. Initial Potassium Replacement in Diabetic Ketoacidosis: The Unnoticed Area of Gap Full Text available with Trip Pro

Initial Potassium Replacement in Diabetic Ketoacidosis: The Unnoticed Area of Gap 29619008 2018 11 14 1664-2392 9 2018 Frontiers in endocrinology Front Endocrinol (Lausanne) Initial Potassium Replacement in Diabetic Ketoacidosis: The Unnoticed Area of Gap. 109 10.3389/fendo.2018.00109 Usman Atif A School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia. eng Journal Article 2018 03 21 Switzerland Front Endocrinol (Lausanne) 101555782 1664-2392 cardiovascular diseases (...) diabetic ketoacidosis hypokalemia mortality potassium replacement treatment outcome 2018 01 16 2018 03 05 2018 4 6 6 0 2018 4 6 6 0 2018 4 6 6 1 epublish 29619008 10.3389/fendo.2018.00109 PMC5871863 N Engl J Med. 1982 Dec 23;307(26):1603-10 6815530 Arch Intern Med (Chic). 1947 Dec;80(6):728-38 18897476 Am J Med. 1981 Sep;71(3):456-67 7025622 Diabetes Care. 2006 Dec;29(12):2739-48 17130218 J Clin Endocrinol Metab. 1948 Aug;8(8):658-65 18877063 Am J Nephrol. 2013;38(1):50-7 23817179 Can J Diabetes. 2016

2018 Frontiers in endocrinology

5. Renal replacement therapy and conservative management

Renal replacement therapy and conservative management Renal replacement ther Renal replacement therap apy and y and conservativ conservative management e management NICE guideline Published: 3 October 2018 nice.org.uk/guidance/ng107 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful (...) in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Renal replacement therapy and conservative management (NG107) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 33Contents

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

6. Chemical substitutions in the selectivity filter of potassium channels do not rule out constricted-like conformations for C-type inactivation Full Text available with Trip Pro

Chemical substitutions in the selectivity filter of potassium channels do not rule out constricted-like conformations for C-type inactivation In many K+ channels, prolonged activating stimuli lead to a time-dependent reduction in ion conduction, a phenomenon known as C-type inactivation. X-ray structures of the KcsA channel suggest that this inactivated state corresponds to a "constricted" conformation of the selectivity filter. However, the functional significance of the constricted (...) conformation has become a matter of debate. Functional and structural studies based on chemically modified semisynthetic KcsA channels along the selectivity filter led to the conclusion that the constricted conformation does not correspond to the C-type inactivated state. The main results supporting this view include the observation that C-type inactivation is not suppressed by a substitution of D-alanine at Gly77, even though this modification is believed to lock the selectivity filter into its conductive

2017 Proceedings of the National Academy of Sciences of the United States of America

7. Potassium Replacement

Potassium Replacement Potassium Replacement Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Potassium Replacement Potassium (...) Replacement Aka: Potassium Replacement , Potassium Supplementation II. Indications III. Precautions is typically needed in conjunction with Adjust protocol for renal disease : < 30 ml/hour : > 3.0 mg/dl IV. Preparations Extended release tablets (preferred) Order generic chloride ER ($15 per month) KDUR brand-name is not available in U.S. as of 2016 Immediate-release powder Expensive ($290 per month) Diluted in liquid and are less than palatable Better tolerated in divided dosing (20 mEq at a time

2018 FP Notebook

8. Effect of low-sodium salt substitutes on blood pressure, detected hypertension, stroke and mortality (Abstract)

Effect of low-sodium salt substitutes on blood pressure, detected hypertension, stroke and mortality A systematic review and meta-analysis was conducted to assess the efficacy of low-sodium salt substitutes (LSSS) as a potential intervention to reduce cardiovascular (CV) diseases.Five engines and ClinicalTrials.gov were searched from inception to May 2018. Randomised controlled trials (RCTs) enrolling adult hypertensive or general populations that compared detected hypertension, systolic blood (...) heterogeneous. Effects were similar across hypertensive, normotensive and mixed populations. LSSS decreased SBP (MD -7.81 mm Hg, 95% CI -9.47 to -6.15, p<0.00001) and DBP (MD -3.96 mm Hg, 95% CI -5.17 to -2.74, p<0.00001) compared with control. Significant increases in urinary potassium (MD 11.46 mmol/day, 95% CI 8.36 to 14.55, p<0.00001) and calcium excretion (MD 2.39 mmol/day, 95% CI 0.52 to 4.26, p=0.01) and decreases in urinary sodium excretion (MD -35.82 mmol/day, 95% CI -57.35 to -14.29, p=0.001) were

2019 EvidenceUpdates

9. Effects of Dietary Sodium and Potassium Intake on Chronic Disease Outcomes and Risks

hypertension. • Use of potassium-containing salt substitutes in the diet to reduce sodium intake most likely reduces blood pressure in adults. • Increasing potassium intake most likely decreases blood pressure in adults with hypertension. • All-cause mortality may be associated with sodium intake. • Reduced sodium intake may decrease the risk for combined CVD morbidity and mortality.iii This report is based on research conducted by the RAND Southern California Evidence-based Practice Center under contract (...) /morbidity and a composite outcome of any CVD events (low SoE). Although sodium levels appear to be associated with all-cause mortality (low SoE), the shape of this relationship could not be determined (insufficient SoE), and evidence from prospective cohort studies was insufficient to draw conclusions regarding associations with combined CVD morbidity/mortality and stroke risk. Use of potassium salt substitutes in place of sodium chloride and increasing potassium intake itself through the use

2018 Effective Health Care Program (AHRQ)

10. Sodium and Potassium Intake: Effects on Chronic Disease Outcomes and Risks

hypertension. • Use of potassium-containing salt substitutes in the diet to reduce sodium intake most likely reduces blood pressure in adults. • Increasing potassium intake most likely decreases blood pressure in adults with hypertension. • All-cause mortality may be associated with sodium intake. • Reduced sodium intake may decrease the risk for combined CVD morbidity and mortality.iii This report is based on research conducted by the RAND Southern California Evidence-based Practice Center under contract (...) /morbidity and a composite outcome of any CVD events (low SoE). Although sodium levels appear to be associated with all-cause mortality (low SoE), the shape of this relationship could not be determined (insufficient SoE), and evidence from prospective cohort studies was insufficient to draw conclusions regarding associations with combined CVD morbidity/mortality and stroke risk. Use of potassium salt substitutes in place of sodium chloride and increasing potassium intake itself through the use

2018 Effective Health Care Program (AHRQ)

11. The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease

The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease The NxStage System One NX1000-1 home The NxStage System One NX1000-1 home haemodialysis de haemodialysis device for renal replacement vice for renal replacement ther therap apy in chronic kidne y in chronic kidney disease y disease Medtech innovation briefing Published: 19 November 2014 nice.org.uk/guidance/mib12 pathways Summary Summary The NxStage System One is a haemodialysis (...) system for renal replacement therapy to be used at home or while travelling. The system can run from standard home electricity and water supplies, and is smaller than standard home haemodialysis systems. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 42Effectiv Effectiveness eness The available evidence comes from 7 published studies (reported in 9 publications) involving a total of 12,604 people. Four small

2014 National Institute for Health and Clinical Excellence - Advice

12. Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan. (Abstract)

Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan. To control hyperthyroidism due to Graves' disease, antithyroid drugs should be administered. Several studies have shown that exposure to methimazole (MMI) during the first trimester of pregnancy increases the incidence of specific congenital anomalies that are collectively (...) referred to as MMI embryopathy. Congenital anomalies associated with exposure to propylthiouracil (PTU) have also recently been reported.This study investigated whether substituting potassium iodide (KI) for MMI in the first trimester would result in a lower incidence of major congenital anomalies than continuing treatment with MMI alone. The cases of 283 women with Graves' disease (GD) were reviewed whose treatment was switched from MMI to KI in the first trimester (iodine group), as well as the cases

2015 Thyroid

13. Is Potassium Supplementation Beneficial in Hospitalized Patients?

. 2015 Jan;128(1):60-7. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med. 2000 Sep 11;160(16):2429-36. Review. Conway R, Creagh D, Byrne DG, O’Riordan D, Silke B. Serum potassium levels as an outcome determinant in acute medical admissions. Clin Med (Lond). 2015 Jun;15(3):239-43. Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among (...) Is Potassium Supplementation Beneficial in Hospitalized Patients? Is Potassium Supplementation Beneficial in Hospitalized Patients? – Clinical Correlations Search Is Potassium Supplementation Beneficial in Hospitalized Patients? October 25, 2017 6 min read By Sara Stream, MD Peer Reviewed As resident physicians, we are taught to supplement serum potassium to a goal level of 4.0 mEq/L in all hospitalized patients. While the dangers of severe potassium abnormalities are well established

2017 Clinical Correlations

14. Association between mortality and replacement solution bicarbonate concentration in continuous renal replacement therapy: A propensity-matched cohort study. Full Text available with Trip Pro

Association between mortality and replacement solution bicarbonate concentration in continuous renal replacement therapy: A propensity-matched cohort study. Given the known deleterious effects seen with bicarbonate supplementation for acidemia, we hypothesized that utilizing high bicarbonate concentration replacement solution in continuous venovenous hemofiltration (CVVH) would be independently associated with higher mortality.In a propensity score-matched historical cohort study conducted (...) at a single tertiary care center from December 9, 2006, through December 31, 2009, a total of 287consecutive adult critically ill patients with Stage III acute kidney injury (AKI) requiring CVVH were enrolled. We excluded patients on maintenance dialysis, those who received other modalities of continuous renal replacement therapies, and patients that received a mixed of 22 and 32 mEq/L bicarbonate solution pre- and post-filter. The primary outcome was in-hospital and 90-day mortality rates.Among enrollees

2017 PLoS ONE

15. Effects of salt substitute on home blood pressure differs according to age and degree of blood pressure in hypertensive patients and their families. (Abstract)

of this current study was to assess the effects of a low-sodium and high-potassium salt substitute on HBP among hypertensive patients and their family members.A total of 220 households (including 220 hypertensive patients and 380 their families) were randomly assigned to the regular salt or salt substitute groups. HBP was measured at the beginning, 3rd, 6th, and 12th months. Among the patients (n = 220), only home systolic blood pressure (HSBP) was significantly reduced, by an adjusted baseline BP of 4.2 mm (...) Effects of salt substitute on home blood pressure differs according to age and degree of blood pressure in hypertensive patients and their families. It is known that home blood pressure (HBP) is a more reliable assessment of hypertension treatments than clinical blood pressure (BP). Despite this, HBP response to a salt substitute has only been evaluated by one study which, did not look at the salt substitute's effect on family members and did not analyze by age, gender, or BP degree. The aim

2018 Clinical and experimental hypertension (New York, N.Y. : 1993) Controlled trial quality: uncertain

16. Neuropsiquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study

Frame: 24 weeks ] Identify patterns of different metabolic marker 18F-fluorodeoxyglucose (18F-FDG) uptake in patients suffering from central nervous system toxicity in relation to the use of Dolutegravir after replacement with Raltegravir. Observe if the anatomic-functional pattern of these patients changes after the substitution of Dolutegravir by Raltegravir. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal (...) Neuropsiquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

17. Targeting matrix metalloproteinases with novel diazepine substituted cinnamic acid derivatives: design, synthesis, in vitro and in silico studies Full Text available with Trip Pro

inhibitors, should be an important goal in lung cancer therapy. In the present study, an effort has been made to develop new anti-metastatic and anti-invasive agents, wherein a series of novel diazepine substituted cinnamic acid derivatives were designed, synthesized and assayed for their inhibitory activities on MMP-2 and MMP-9. These derivatives were prepared via microwave assisted reaction of tert-butyl (3-cinnamamidopropyl)carbamate derivatives mixed with 2,3-dibromopropanoic acid and potassium (...) Targeting matrix metalloproteinases with novel diazepine substituted cinnamic acid derivatives: design, synthesis, in vitro and in silico studies Lung cancer is the notable cause of cancer associated deaths worldwide. Recent studies revealed that the expression of matrix metalloproteinases (MMPs) is extremely high in lung tumors compared with non-malignant lung tissue. MMPs (-2 and -9) play an important part in tumor development and angiogenesis, which suggests that creating potent MMP-2 and -9

2018 Chemistry Central journal

18. Association between salt substitutes/enhancers and changes in sodium levels in fast-food restaurants: a cross-sectional analysis Full Text available with Trip Pro

chain (n = 12) for which ingredient data were available. The most common substitutes/enhancers were yeast extracts (in 30% of foods), calcium chloride (28%), monosodium glutamate (14%) and potassium chloride (12%). Sodium levels in foods that contained substitutes/enhancers decreased significantly more (190 ± 42 mg/serving) over the study period than those in foods that did not contain a substitute/enhancer (40 ± 17 mg/serving, p < 0.001).Salt substitutes and enhancers are prevalent in restaurant (...) Association between salt substitutes/enhancers and changes in sodium levels in fast-food restaurants: a cross-sectional analysis Restaurant foods have high sodium levels, and efforts have been made to promote reductions. The objective of this study was to understand if salt substitutes and enhancers are associated with changes in sodium levels in fast-food restaurants.A longitudinal database (MENU-FLIP) containing nutrition information for Canadian chain restaurants with 20 or more locations

2018 CMAJ open

19. Can we predict when to start renal replacement therapy in patients with chronic kidney disease using 6 months of clinical data? Full Text available with Trip Pro

Can we predict when to start renal replacement therapy in patients with chronic kidney disease using 6 months of clinical data? We aimed to develop a model of chronic kidney disease (CKD) progression for predicting the probability and time to progression from various CKD stages to renal replacement therapy (RRT), using 6 months of clinical data variables routinely measured at healthcare centers.Data were derived from the electronic medical records of Ajou University Hospital, Suwon, South Korea (...) , respectively. The integral mean was the most powerful explanatory (R2 = 0.404) variable among the 8 modified values. Ten variables (age, sex, diabetes mellitus[DM], polycystic kidney disease[PKD], serum albumin, serum hemoglobin, serum phosphorus, serum potassium, eGFR (calculated by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]), and urinary protein) were included in the final risk prediction model for CKD stage 3 (R2 = 0.330). Ten variables (age, sex, DM, GN, PKD, serum hemoglobin, serum

2018 PLoS ONE

20. Planning, initiation & withdrawal of Renal Replacement Therapy

Planning, initiation & withdrawal of Renal Replacement Therapy - 1 - CLINICAL PRACTICE GUIDELINE Planning, Initiating and Withdrawal of Renal Replacement Therapy UK Renal Association 6 th Edition Final Version (based on literature up to Feb 2013) Graham Warwick, Consultant Nephrologist Andrew Mooney, Consultant Nephrologist Lynne Russon, Consultant in Palliative Medicine, Rebecca Hardy, SpR in Nephrology Posted at www.renal.org/guidelines Please check for updates Please send feedback (...) for the next edition to Graham Warwick at graham.warwick@uhl-tr.nhs.uk or Andrew Mooney at andrew.mooney@leedsth.nhs.uk - 2 - Contents Introduction Summary of Clinical Practice Guidelines for Planning, Initiating and Withdrawal of Renal Replacement Therapy 1. Timely nephrology referral (Guidelines 1.1-1.2) 2. Nephrology follow-up (Guidelines 2.1-2.3) 3. Preparing for renal replacement therapy (Guidelines 3.1-3.7) 4. Educating patients and carers for renal replacement therapy (Guidelines 4.1-4.3) 5

2014 Renal Association

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>